APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rheumatic Disorders Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rheumatic Disorders Drug Market Analysis and Forecast 2026-2032

Report ID 174032760222 December 2025191 pages

Choose your research edition.

Industry ResearchRheumatic Disorders Drug Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rheumatic Disorders Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Rheumatic Disorders Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rheumatic Disorders Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Rheumatic Disorders Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Rheumatic Disorders Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rheumatic Disorders Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rheumatic Disorders Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rheumatic Disorders Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rheumatic Disorders Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rheumatic Disorders Drug include Bristol-Myers Squibb, AbbVie, Amgen, Pfizer, Eli Lilly, Roche, Novartis and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rheumatic Disorders Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rheumatic Disorders Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Rheumatic Disorders Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rheumatic Disorders Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rheumatic Disorders Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rheumatic Disorders Drug revenue, projected growth trends, production technology, application and end-user industry.

Rheumatic Disorders Drug Segment by Company

Bristol-Myers Squibb

AbbVie

Amgen

Pfizer

Eli Lilly

Roche

Novartis

Johnson & Johnson

Rheumatic Disorders Drug Segment by Type

Acting on Interleukins and Interleukin Receptors

Acting on Protein Kinases

Acting on Hormones and Hormone Receptors

Acting on Cell Surface Antigens

Acting on Tumor Necrosis Factor-Alpha

Others

Rheumatic Disorders Drug Segment by Application

Psoriatic Arthritis

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Osteoporosis

Osteoarthritis

Others

Rheumatic Disorders Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disorders Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disorders Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disorders Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rheumatic Disorders Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rheumatic Disorders Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rheumatic Disorders Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rheumatic Disorders Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Acting on Interleukins and Interleukin Receptors Major Player Table 3. Acting on Protein Kinases Major Player Table 4. Acting on Hormones and Hormone Receptors Major Player Table 5. Acting on Cell Surface Antigens Major Player Table 6. Acting on Tumor Necrosis Factor-Alpha Major Player Table 7. Others Major Player Table 8. Global Rheumatic Disorders Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Psoriatic Arthritis Major Player Table 10. Systemic Lupus Erythematosus Major Player Table 11. Rheumatoid Arthritis Major Player Table 12. Osteoporosis Major Player Table 13. Osteoarthritis Major Player Table 14. Others Major Player Table 15. Rheumatic Disorders Drug Industry Trends Table 16. Rheumatic Disorders Drug Industry Drivers Table 17. Rheumatic Disorders Drug Industry Opportunities and Challenges Table 18. Rheumatic Disorders Drug Industry Restraints Table 19. Global Rheumatic Disorders Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Rheumatic Disorders Drug Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Rheumatic Disorders Drug Market Share by Region (2021-2026) Table 22. Global Rheumatic Disorders Drug Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Rheumatic Disorders Drug Market Share by Region (2027-2032) Table 24. Global Rheumatic Disorders Drug Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Rheumatic Disorders Drug Revenue Market Share by Players (2021-2026) Table 26. Global Rheumatic Disorders Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Rheumatic Disorders Drug Key Players Headquarters & Area Served Table 28. Global Rheumatic Disorders Drug Players, Product Type & Application Table 29. Global Rheumatic Disorders Drug Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Rheumatic Disorders Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Rheumatic Disorders Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Rheumatic Disorders Drug Revenue Market Share by Type (2021-2026) Table 36. Global Rheumatic Disorders Drug Revenue Market Share by Type (2027-2032) Table 37. Global Rheumatic Disorders Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Rheumatic Disorders Drug Revenue Market Share by Application (2021-2026) Table 41. Global Rheumatic Disorders Drug Revenue Market Share by Application (2027-2032) Table 42. Bristol-Myers Squibb Company Information Table 43. Bristol-Myers Squibb Business Overview Table 44. Bristol-Myers Squibb Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Bristol-Myers Squibb Rheumatic Disorders Drug Product Portfolio Table 46. Bristol-Myers Squibb Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Rheumatic Disorders Drug Product Portfolio Table 51. AbbVie Recent Development Table 52. Amgen Company Information Table 53. Amgen Business Overview Table 54. Amgen Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Amgen Rheumatic Disorders Drug Product Portfolio Table 56. Amgen Recent Development Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Pfizer Rheumatic Disorders Drug Product Portfolio Table 61. Pfizer Recent Development Table 62. Eli Lilly Company Information Table 63. Eli Lilly Business Overview Table 64. Eli Lilly Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Eli Lilly Rheumatic Disorders Drug Product Portfolio Table 66. Eli Lilly Recent Development Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Roche Rheumatic Disorders Drug Product Portfolio Table 71. Roche Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Novartis Rheumatic Disorders Drug Product Portfolio Table 76. Novartis Recent Development Table 77. Johnson & Johnson Company Information Table 78. Johnson & Johnson Business Overview Table 79. Johnson & Johnson Rheumatic Disorders Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Johnson & Johnson Rheumatic Disorders Drug Product Portfolio Table 81. Johnson & Johnson Recent Development Table 82. North America Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Rheumatic Disorders Drug Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Rheumatic Disorders Drug Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Rheumatic Disorders Drug Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Rheumatic Disorders Drug Revenue by Country (US$ Million) & (2027-2032) Table 96. China Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. China Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. China Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 99. China Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Rheumatic Disorders Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Rheumatic Disorders Drug Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Rheumatic Disorders Drug Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Rheumatic Disorders Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Rheumatic Disorders Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Rheumatic Disorders Drug Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Rheumatic Disorders Drug Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Rheumatic Disorders Drug Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Rheumatic Disorders Drug Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Rheumatic Disorders Drug Image Figure 2. Global Rheumatic Disorders Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rheumatic Disorders Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Acting on Interleukins and Interleukin Receptors Image Figure 5. Acting on Protein Kinases Image Figure 6. Acting on Hormones and Hormone Receptors Image Figure 7. Acting on Cell Surface Antigens Image Figure 8. Acting on Tumor Necrosis Factor-Alpha Image Figure 9. Others Image Figure 10. Global Rheumatic Disorders Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Rheumatic Disorders Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Psoriatic Arthritis Image Figure 13. Systemic Lupus Erythematosus Image Figure 14. Rheumatoid Arthritis Image Figure 15. Osteoporosis Image Figure 16. Osteoarthritis Image Figure 17. Others Image Figure 18. Global Rheumatic Disorders Drug Market Size (US$ Million) & (2021-2032) Figure 19. Global Rheumatic Disorders Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Rheumatic Disorders Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Rheumatic Disorders Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Rheumatic Disorders Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Rheumatic Disorders Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Rheumatic Disorders Drug Revenue Market Share by Type (2021-2032) Figure 26. Global Rheumatic Disorders Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Rheumatic Disorders Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Rheumatic Disorders Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Rheumatic Disorders Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Rheumatic Disorders Drug Revenue Share by Type (2021-2032) Figure 31. North America Rheumatic Disorders Drug Revenue Share by Application (2021-2032) Figure 32. North America Rheumatic Disorders Drug Revenue Share by Country (2021-2032) Figure 33. United States Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Rheumatic Disorders Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Rheumatic Disorders Drug Revenue Share by Type (2021-2032) Figure 38. Europe Rheumatic Disorders Drug Revenue Share by Application (2021-2032) Figure 39. Europe Rheumatic Disorders Drug Revenue Share by Country (2021-2032) Figure 40. Germany Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Rheumatic Disorders Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Rheumatic Disorders Drug Revenue Share by Type (2021-2032) Figure 50. China Rheumatic Disorders Drug Revenue Share by Application (2021-2032) Figure 51. Asia Rheumatic Disorders Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Rheumatic Disorders Drug Revenue Share by Type (2021-2032) Figure 53. Asia Rheumatic Disorders Drug Revenue Share by Application (2021-2032) Figure 54. Asia Rheumatic Disorders Drug Revenue Share by Region (2021-2032) Figure 55. Japan Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Rheumatic Disorders Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Rheumatic Disorders Drug Revenue Share by Type (2021-2032) Figure 63. SAMEA Rheumatic Disorders Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA Rheumatic Disorders Drug Revenue Share by Country (2021-2032) Figure 65. Brazil Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Rheumatic Disorders Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Acting on Interleukins and Interleukin Receptors
  • Acting on Protein Kinases
  • Acting on Hormones and Hormone Receptors
  • Acting on Cell Surface Antigens
  • Acting on Tumor Necrosis Factor-Alpha
  • Others
Applications
  • Psoriatic Arthritis
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Osteoporosis
  • Osteoarthritis
  • Others
Companies covered
  • Bristol-Myers Squibb
  • AbbVie
  • Amgen
  • Pfizer
  • Eli Lilly
  • Roche
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rheumatic Disorders Drug Market by Type
  3. 1.2.1 Global Rheumatic Disorders Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Acting on Interleukins and Interleukin Receptors
  5. 1.2.3 Acting on Protein Kinases
  6. 1.2.4 Acting on Hormones and Hormone Receptors
  7. 1.2.5 Acting on Cell Surface Antigens
  8. 1.2.6 Acting on Tumor Necrosis Factor-Alpha
  9. 1.2.7 Others
  10. 1.3 Rheumatic Disorders Drug Market by Application
  11. 1.3.1 Global Rheumatic Disorders Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Psoriatic Arthritis
  13. 1.3.3 Systemic Lupus Erythematosus
  14. 1.3.4 Rheumatoid Arthritis
  15. 1.3.5 Osteoporosis
  16. 1.3.6 Osteoarthritis
  17. 1.3.7 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Rheumatic Disorders Drug Market Dynamics
  1. 2.1 Rheumatic Disorders Drug Industry Trends
  2. 2.2 Rheumatic Disorders Drug Industry Drivers
  3. 2.3 Rheumatic Disorders Drug Industry Opportunities and Challenges
  4. 2.4 Rheumatic Disorders Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rheumatic Disorders Drug Market Perspective (2021-2032)
  2. 3.2 Global Rheumatic Disorders Drug Growth Trends by Region
  3. 3.2.1 Global Rheumatic Disorders Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rheumatic Disorders Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Rheumatic Disorders Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rheumatic Disorders Drug Revenue by Players
  2. 4.1.1 Global Rheumatic Disorders Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Rheumatic Disorders Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rheumatic Disorders Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rheumatic Disorders Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rheumatic Disorders Drug Key Players Headquarters & Area Served
  7. 4.4 Global Rheumatic Disorders Drug Players, Product Type & Application
  8. 4.5 Global Rheumatic Disorders Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rheumatic Disorders Drug Market CR5 and HHI
  11. 4.6.3 2025 Rheumatic Disorders Drug Tier 1, Tier 2, and Tier 3
5 Rheumatic Disorders Drug Market Size by Type
  1. 5.1 Global Rheumatic Disorders Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 5.3 Global Rheumatic Disorders Drug Revenue Market Share by Type (2021-2032)
6 Rheumatic Disorders Drug Market Size by Application
  1. 6.1 Global Rheumatic Disorders Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rheumatic Disorders Drug Revenue by Application (2021-2032)
  3. 6.3 Global Rheumatic Disorders Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Rheumatic Disorders Drug Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 AbbVie
  8. 7.2.1 AbbVie Company Information
  9. 7.2.2 AbbVie Business Overview
  10. 7.2.3 AbbVie Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Rheumatic Disorders Drug Product Portfolio
  12. 7.2.5 AbbVie Recent Developments
  13. 7.3 Amgen
  14. 7.3.1 Amgen Company Information
  15. 7.3.2 Amgen Business Overview
  16. 7.3.3 Amgen Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Rheumatic Disorders Drug Product Portfolio
  18. 7.3.5 Amgen Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Rheumatic Disorders Drug Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Rheumatic Disorders Drug Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Rheumatic Disorders Drug Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Rheumatic Disorders Drug Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Johnson & Johnson
  44. 7.8.1 Johnson & Johnson Company Information
  45. 7.8.2 Johnson & Johnson Business Overview
  46. 7.8.3 Johnson & Johnson Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson & Johnson Rheumatic Disorders Drug Product Portfolio
  48. 7.8.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Rheumatic Disorders Drug Revenue (2021-2032)
  2. 8.2 North America Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Rheumatic Disorders Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Rheumatic Disorders Drug Revenue by Type (2027-2032)
  5. 8.3 North America Rheumatic Disorders Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Rheumatic Disorders Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Rheumatic Disorders Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Rheumatic Disorders Drug Revenue by Application (2027-2032)
  9. 8.5 North America Rheumatic Disorders Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Rheumatic Disorders Drug Revenue by Country
  11. 8.6.1 North America Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rheumatic Disorders Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Rheumatic Disorders Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Rheumatic Disorders Drug Revenue (2021-2032)
  2. 9.2 Europe Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rheumatic Disorders Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rheumatic Disorders Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Rheumatic Disorders Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rheumatic Disorders Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rheumatic Disorders Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rheumatic Disorders Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Rheumatic Disorders Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rheumatic Disorders Drug Revenue by Country
  11. 9.6.1 Europe Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rheumatic Disorders Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rheumatic Disorders Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Rheumatic Disorders Drug Revenue (2021-2032)
  2. 10.2 China Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Rheumatic Disorders Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Rheumatic Disorders Drug Revenue by Type (2027-2032)
  5. 10.3 China Rheumatic Disorders Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Rheumatic Disorders Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Rheumatic Disorders Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Rheumatic Disorders Drug Revenue by Application (2027-2032)
  9. 10.5 China Rheumatic Disorders Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rheumatic Disorders Drug Revenue (2021-2032)
  2. 11.2 Asia Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rheumatic Disorders Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rheumatic Disorders Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Rheumatic Disorders Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rheumatic Disorders Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rheumatic Disorders Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rheumatic Disorders Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Rheumatic Disorders Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rheumatic Disorders Drug Revenue by Country
  11. 11.6.1 Asia Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rheumatic Disorders Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rheumatic Disorders Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rheumatic Disorders Drug Revenue (2021-2032)
  2. 12.2 SAMEA Rheumatic Disorders Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rheumatic Disorders Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rheumatic Disorders Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rheumatic Disorders Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rheumatic Disorders Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rheumatic Disorders Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rheumatic Disorders Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rheumatic Disorders Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rheumatic Disorders Drug Revenue by Country
  11. 12.6.1 SAMEA Rheumatic Disorders Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rheumatic Disorders Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rheumatic Disorders Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst